Neonates with necrotizing enterocolitis (NEC) have higher calprotectin levels in stool than do healthy neonates. However, it is not known whether high stool calprotectin at the onset of bowel symptoms identifies neonates who truly have NEC vs other bowel disorders. STUDY DESIGN: Neonates were eligible for this study when an x-ray was ordered to 'rule-out NEC'. Stool calprotectin was quantified at that time and in a follow-up stool. Each episode was later categorized as NEC or not NEC. The location of calprotectin in the bowel was determined by immunohistochemistry. RESULTS: Neonates with NEC had higher initial and follow-up stool calprotectin levels than did neonates without NEC. Calprotectin in bowel from neonates with NEC was within neutrophil extracellular traps (NETs). CONCLUSION: At the onset of signs concerning for NEC, fecal calprotectin is likely to be higher in neonates with NEC. Calprotectin in their stools is exported from neutrophils via NETs.
INTRODUCTION
Necrotizing enterocolitis (NEC) can be a life-threatening disorder and we need more accurate ways to recognize cases during its earliest stages. [1] [2] [3] [4] When the initial x-rays are inconclusive, we typically stop the feedings, initiate antibiotics and parenteral nutrition, and order serial abdominal x-rays. 5 If a reliable way were available to confirm the diagnosis of NEC at the onset of abdominal distention when x-rays are not diagnostic, that information could help guide the course of treatment. 5 Calprotectin is an anti-bacterial protein found in neutrophils, monocytes and macrophages. It constitutes~60% of the cytosolic proteins of neutrophils. [6] [7] [8] Calprotectin binds to calcium, stabilizing it and preventing degradation in the intestine. 9 Adults with inflammatory bowel disorders have high stool calprotectin concentrations. [6] [7] [8] [9] [10] [11] [12] High levels of calprotectin in stool is likely from migration of activated neutrophils across gastrointestinal epithelial membranes. 11 Previous studies report higher calprotectin levels in stools of neonates with NEC, compared with stools of healthy control neonates. 8, 10, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] However, it is not clear whether measuring stool calprotectin at the onset of intestinal signs would discriminate between cases that are eventually going to be diagnosed as NEC vs more benign forms of feeding intolerance. We prospectively tested this possibility.
As part of this study, we also investigated the source of calprotectin in the intestine of neonates with NEC. Calprotectin is located within neutrophils. As part of the innate immune response, neutrophils can eject nuclear chromatin and bactericidal proteins known as neutrophil extracellular traps (NETs) to trap and kill microorganisms. 26, 27 NETs contain calprotectin. 28 We sought to further define the relationship between calprotectin and NETs in bowel tissue from neonates with NEC.
MATERIALS AND METHODS

Study design and populations
This was a prospective pilot study conducted in two Intermountain Healthcare Neonatal Intensive Care Units: McKay-Dee Hospital, Ogden, UT, USA and Utah Valley Regional Medical Center, Provo, UT, USA. The Intermountain Healthcare Institutional Review Board approved the protocol and an informed consent document was signed by the parents of all participating neonates. Intermountain Healthcare is a not-for-profit system that owns and operates 22 hospitals in Utah and Idaho. International Review Board approval for the calprotectin immunohistochemical and immunocytochemical experiments with the analysis of NETosis was obtained through the University of Utah. The University of Utah International Review Board classified this study as exempt from requiring signed consent because of the deidentified status of the tissues.
When a clinician ordered an abdominal x-ray to 'rule-out NEC', the neonate was considered eligible for this study. Any stools at the time of the x-ray, or preceding the x-ray by o2 h, or within the 12-h period following the x-ray, were placed in a special stool-collection vial (minimum 1 g) for calprotectin analysis as a research study. Parents were contacted within several hours of the qualifying x-ray and told of the study. If the parents consented, the stool was submitted to ARUP Laboratories for fecal calprotectin assay. If the parents refused, the stool was discarded. For consented patients, a repeat stool sample was also sent for calprotectin assay within 72 h of the qualifying x-ray. If a second stool was not passed by 72 h, the next-passed stool was used and the time recorded. The fecal calprotectin tests were not billed to families or third-party payers, but were paid by a research grant. The calprotectin levels were not placed in the medical record or reported to the clinicians. Consent sought from parents after an x-ray was ordered for "rule-out NEC" This was a convenience sample of 30 episodes of 'rule-out NEC'. Thirty episodes was selected on the basis of the funding available for the study. Patients were only entered into the protocol when a study nurse or study neonatologist was available to explain the study and provide informed consent for parents. The research did not involve ordering any other laboratory tests or x-rays; however, clinically indicated blood tests and x-rays, physical examination findings and clinical decisions on the study patients were available to the research team and included in the study analysis.
During the study period, the two neonatal intensive care units had a consistent clinical approach, which included feeding mother's own milk or pasteurized human milk; 29 using restrictive erythrocyte transfusion guidelines; 30 using delayed cord clamping or cord milking for preterm delivery; 31 obtaining the initial laboratory blood work from otherwise discarded fetal blood in the umbilical cord; 32 and not providing enteral feedings during blood transfusions.
One week or more following the study entry, study staff assembled all relevant clinical and research data, including the diagnosis arrived at by the clinicians regarding the cause of the abdominal distention. Causes were categorized by the research staff, as shown in Table 1 , as either not NEC (with hematochezia or without hematochezia), Medical NEC (stage II) or surgical NEC (stage III). Cases were evaluated for the possibility of misdiagnosis, that is, for spontaneous intestinal perforation as a potential confounding diagnosis.
Calprotectin assay
The PhiCal fecal calprotectin immunoassay (Genova Diagnostics, Ashville, NC, USA) is an enzyme-linked immunoassay system with colorimetric detection, and was performed at ARUP Laboratories (Salt Lake City, UT, USA) according to the manufacturer's instructions. The test uses a polyclonal antibody against calprotectin. Calprotectin present in the diluted sample is bound by the antibody absorbed to the surface of the plastic well. The enzyme-conjugated antibody binds to the captured antigen and subsequently the enzyme catalyzes the conversion of the substrate to a colored product. The intensity of the color is proportional to the amount of conjugate bound, and thus to the amount of captured calprotectin. Concentration of calprotectin in the samples is calculated using a standard, provided in the test kit.
Localization of calprotectin to NETs
PMNs were isolated from acid citrate dextrose or EDTA-anticoagulated venous blood from healthy adults under protocols approved by the University of Utah International Review Board. PMN suspensions (496% pure) were prepared by positive immunoselection using anti-CD15-coated microbeads and an auto-MACS cell sorter (Miltenyi Biotec, Inc., San Diego, CA, USA) and were resuspended at 2 × 10 6 cells per ml concentration in serum-free M-199 media at 37°C in 5% CO 2 /95% air. Qualitative assessment of NET formation was performed as reported previously. 26, 33 Briefly, primary PMNs isolated from healthy adults (2 × 10 6 cells per ml) Figure 2 . Stool calprotectin levels in 30 episodes of 'rule-out NEC'. Time '0' is the time the x-ray was obtained to 'rule-out NEC'. Paired followup levels of stools passed after the qualifying x-ray are connected by dashed (NEC) or solid (not NEC) lines. One week or more after the qualifying 'rule-out NEC' x-ray, each of the 30 episodes was assigned as most likely having been due to NEC or not having been due to NEC. NEC, necrotizing enterocolitis.
were incubated with control buffer or stimulated with lipopolysaccharide (100 ng ml − 1 ) for 1 h at 37°C in 5% CO 2 /95% air on glass coverslips coated with poly-L-lysine. After stimulation, PMNs were gently washed with phosphate-buffered saline and fixed with 4% paraformaldehyde for 10 min, followed by permeabilization with Triton X-100 for 10 min. Calprotectin protein expression was detected via immunocytochemistry using a fluorescein isothiocyanate-conjugated anti-human calprotectin primary antibody (LifeSpan BioSciences, Inc., Seattle, WA, USA; 1:100 dilution). Confocal microscopy was accomplished using an FV1000 1 × 81 confocal microscope and FluoView software (Olympus America Inc., Melville, NY, USA). Both × 20 and × 60 objectives were used. Z-series images were obtained at a step size 1 μm over a range of 20 μm for each field. Olympus FluoView (Olympus America Inc.) and Adobe Photoshop CS (Adobe Systems, San Jose, CA, USA) software were used for image processing.
Localization of calprotectin within the bowel of neonates with NEC Gastrointestinal tissue samples from surgically treated prematurely born neonates with NEC (n = 5) were compared using immunohistochemical techniques to gastrointestinal tissue samples processed in parallel from control patients operated on for indications other than NEC (n = 6). Immunohistochemistry on paraffin sections followed established procedures, including dewaxing, rehydration and high temperature antigen retrieval (Vector Unmasking Solution; Vector Laboratories, Burlingame, CA, USA) before blocking. Primary antibodies used in this study were as follows: anti-human calprotectin (LifeSpan BioSciences, Inc.; 1:100 dilution); anti-human neutrophil elastase (Hycult Biotech Inc., Plymouth Meeting, PA, USA; 1:100 dilution). An Alexa-568 goat anti-rabbit secondary antibody (Molecular Probes, ThermoFisher Scientific, Waltham, MA, USA; 1:1000 dilution) was used. Before imaging via confocal microscopy, tissue sections were incubated with DRAQ5 (Cell Signaling Technology, Danvers, MA, USA; 1:1000 dilution) as a DNA counterstain. Confocal microscopy was accomplished as described previously for immunocytochemistry. 26, 33 Statistical analysis
The program used for data collection was a modified subsystem of Clinical Workstation. The 3M Company (Minneapolis, MN, USA) approved the structure and definitions of all data points for use within the program. Data were managed and accessed by authorized data analysts. Means and standard deviations were used to express values in groups that were normally distributed, and medians and interquartile ranges to express values in groups that were not. Differences in categorical variables were assessed using the Fisher exact test or χ 2 for normally distributed data and Tukey's biweight estimator for groups that were not. Statistical analysis used Statit (Midas, Tucson, AZ, USA). Statistical significance was set as Po0.05. The statistical performance of fecal calprotectin was also assessed by receiver operating characteristic curves (IBM SPSS Statistics, version 23.0, Armonk, NY, USA).
RESULTS
We initiated study enrollment at McKay-Dee Hospital, Ogden, Utah, in May 2014 and at Utah Valley Regional Medical Center, Provo, Utah, in June 2014, and concluded in July 2015. As diagramed in Figure 1 , 31 episodes qualified for the study at a time when the study personnel were available to ask parents for study consent. Parental consent was obtained for 30. Figure 1 shows study enrollment, procedures and the eventual clinical diagnosis made for each of the 30 'rule-out NEC' episodes. There were no cases of spontaneous intestinal perforation. This study focused only on cases where NEC was possible but not definite at the onset.
b Pneumatosis was first observed on a repeat x-ray taken in eight neonates at the following times (hours after the initial qualifying x-ray): 2, 3, 6, 24, 24, 24, 24 and 72 h. Portal venous gas was diagnosed in one neonate 24 h after the qualifying x-ray. Free intraperitoneal air was found in one neonate 24 h after the qualifying x-ray. The paired (initial and follow-up) fecal calprotectin levels of the 30 episodes are shown in Figure 2 . Calprotectin levels were higher in the first-sample stools of the 15 with NEC (median 516 μg g , P o 0.0001). The time to passage of the second stool was similar in the 15 who did not have NEC (92 ± 62 h) and in the 15 who did (100 ± 66 h, P o0.665).
Clinical and laboratory findings during the week following the qualifying x-ray are shown in Table 2 . All 15 who were retrospectively judged as having had NEC received antibiotics for ⩾ 5 days and were labeled as having NEC in the medical record. None of the 15 judged as not having had NEC had an x-ray showing pneumatosis, portal venous gas or perforation, and none had thrombocytopenia or neutropenia, or antibiotics for ⩾ 5 days, and none were labeled as having NEC in the medical record.
Ten of the 15 neonates with NEC had a fall in fecal calprotectin between their first-studied stool (655 ± 369 pg g − 1 ) and their second-studied stool (327 ± 368 pg g − 1 ). The other five had an increase, from 331 ± 214 pg g − 1 in the first stool to 1086 ± 299 pg g − 1 in the second (Figure 2, dashed lines) . The 10 where it fell and the 5 where it increased were of similar gestational age at birth (P = 0.55), birth weight (P = 0.39), corrected age at the time the 'rule-out NEC' x-ray was taken (P = 0.49) and length of time between the initial and follow-up stool (P = 0.42). However, in all six with the highest initial calprotectin the subsequent level fell. The five where the level went up had a lower initial value compared with those where the level fell (P o 0.0001).
In the 15 who did not have NEC, bloody stools did not significantly elevate the fecal calprotectin level. Hematochezia (n = 6) (median 101 μg g − 1 stool; first quartile 39 μg g − 1 , third quartile 168 μg g − 1 ) and no hematochezia (n = 9) (median 54 μg g − 1 stool; first quartile 21 μg g − 1 ; third quartile 116 μg g − 1 ; P = 0.074).
Demographic, clinical and laboratory information describing the neonates at the onset of their 'rule-out NEC' episode are shown in Table 2 . None of the 15 episodes of NEC, and none of the 15 episodes that were not NEC, had a blood transfusion in the preceding 48 h. The group of 15 with NEC were of similar birth weight, gestational age, gender, race and postnatal age as the 15 who turned out not to have NEC. Complete blood count (CBC) values obtained with the qualifying x-ray as part of the 'rule-out NEC' evaluation, and any CBC value obtained within 24 h before that evaluation, are included in Table 2 . In the 15 who had NEC the I/T (ratio of immature neutrophils to total neutrophils) neutrophil ratios were slightly higher (P = 0.046) and stool calprotectin levels significantly higher (P o 0.0001). Table 3 shows laboratory information at the onset of the 'rule out NEC' episode. Table 4 shows laboratory results from the 3-day period following the onset of the episode. The one patient with surgical NEC had the highest and the lowest leukocyte counts of the group, the highest I/T neutrophil ratio, and the lowest monocyte and platelet counts. The 15 with NEC had higher initial and follow up stool calprotectin levels than did the 15 who did not have NEC (P o 0.0001). Figure 3 shows receiver operating characteristic analysis, showing curves for both the initial and the follow-up stool levels of calprotectin. Using immunohistochemistry, calprotectin in bowel excised from neonates with NEC was associated with activated neutrophils in NETs. ) for 1 h to stimulate NET formation. Again, gold fluorescence denotes calprotectin protein expression and blue fluorescence denotes DNA. These images are representative of six different replicates using PMNs isolated from six different healthy adults. Bar, 20 μm on (a) row 1, images 1 and 2, 5 μm on (a) row 1, image 3 and row 2, and 10 μm on (b).
DISCUSSION
When a neonatal intensive care unit patient has abdominal distention or other findings that could suggest a diagnosis of NEC, it is sometimes difficult to know if the condition is indeed NEC or is a less pernicious variety of bowel dysfunction. If the initial x-ray shows pneumatosis or portal venous air, a diagnosis of NEC can be straightforward. However, many times the initial radiograph is not definitive and clinicians must devise a plan for treatment without certainty as to whether or not the patient has NEC.
Certain CBC changes can help identify the condition as NEC. 34 These include thrombocytopenia, disturbance in coagulation, anemia, neutrophilia or neutropenia, and a leukocyte 'left shift'. [34] [35] [36] However, we observed relatively minimal CBC changes early in the course of NEC, consistent with a recent report of Maheshwari et al. 37 who reported that inflammatory cytokines did not generally rise until after the onset of NEC. Thuijls et al. 15 also found that at the onset of suspicion for NEC, the platelet count and CRP were not different between those who were eventually diagnosed with NEC vs those with other diagnoses.
In 12 of 13 previous studies, neonates with established NEC had higher stool calprotectin levels compared with healthy controls (refs 8,13-25 and Supplementary Material). We designed the present study as distinctly different than all previous reports. Specifically, we did not study neonates with well-established NEC nor did we study healthy controls. Rather, we examined neonatal intensive care unit patients at the onset of intestinal pathology sufficient to warrant an abdominal x-ray to 'rule-out NEC', and we asked whether the level of calprotectin in the stool at that time could differentiate between those who would go on to a diagnosis of NEC from those who would have a less severe form of feeding intolerance.
Calprotectin is present within neutrophils and is likely to be associated with activated macrophages in the bowel. [37] [38] [39] Neutrophils use several anti-bacterial modalities including degranulation and phagocytosis. In 2004, Brinkmann et al. 40 reported a different mechanism; the ejection of nuclear chromatin and bactericidal proteins in a structure known as NETs to ensnare and kill microorganisms. The process has been termed NETosis. 41 We found that calprotectin in excised NEC-affected bowel is one of the proteins released by neutrophils in association with NETs. Thus, at least some of the calprotectin in stools of neonates with NEC is derived from activated neutrophils migrating to the bowel mucosa and lumen and exporting anti-microbial calprotectin by way of NETosis.
We found that at the onset of abdominal distension that raised a concern for NEC, a higher calprotectin level was indicative of NEC. Hematochezia did not significantly inscrease the calprotectin level. This is consistent with the observation in adult patients that gastrointestinal bleeding of as much as 100 ml per day increases the fecal calprotectin concentration by only 15 μg g − 1 (ARUP Laboratories; http://ltd.aruplab.com/Tests/Pub/0092303). Thus, perhaps a fecal calprotectin level can be of value, in questionable cases, in initially planning the length of NPO, TPN and antibiotics, and in discussions with the family and staff.
We recognize limitations of our study. It is a pilot report involving only 30 episodes. We investigated infants with gastrointestinal signs that prompted a 'R/O NEC' x-ray, and therefore we cannot determine a normal fecal calprotectin reference interval from our data. Fecal calprotectin levels are generally higher in neonates compared with that in older children and adults, 6 and the levels have inter-and intraindividual variability based on gestational age, postnatal age and time of day collected. 11, 12, 14, 16 Thus, creating reference intervals for fecal calprotectin in neonates will be more complex than in older children or adults. Owing to a low rate of surgical NEC in the patients in this study, the stool samples measured for calprotectin and the tissue samples assayed for NETs were obtained from different patients. The one case of surgical NEC occurred before our investigation into the source of fecal calprotectin that prevented us from using that patient's tissue sample. We realize that our evidence that calprotectin in stool originates from activated neutrophils is limited and correlative. However it is the first such evidence in neonates with NEC.
In conclusion, we present pilot data that a fecal calprotectin level at the time of concern for NEC could help distinguish NEC from more benign forms of feeding intolerance. Larger studies are needed to confirm this, and gestational-and postnatal-age reference ranges for fecal calprotectin are also needed.
